Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-MC-01 in interstitial cystitis
NCT04610359Phase 1Unknown
- Sponsor
- Asan Medical Center
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MR-MC-01 in interstitial cystitis (IC), sponsored by Asan Medical Center. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 months. Status: unknown.
02
Drugs
MR-MC-01
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT04610359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610359.